Piper Sandler Maintains Overweight on Neoleukin Therapeutics, Lowers Price Target to $25
Piper Sandler analyst Joseph Catanzaro maintains Neoleukin Therapeutics (NASDAQ:NLTX) with a Overweight and lowers the price target from $30 to $25.
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 147 companies achieved new lows for the year.
Neoleukin Therapeutics Announces Clinical Collaboration With Merck To Evaluate NL-201 In Combination With KEYTRUDA
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a clinical trial
Neoleukin Therapeutics Announced Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at ASH 2021
Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63rd American Society of Hematology (ASH) Annual Meeting and Expos
Neoleukin Therapeutics Q3 EPS $(0.28) Down From $(0.04) YoY
Neoleukin Therapeutics (NASDAQ:NLTX) reported quarterly losses of $(0.28) per share. This is a 600 percent decrease over losses of $(0.04) per share from the same period last year.
Neoleukin Therapeutics Announces Oral Presentation At IDWeek 2021 Of Data Demonstrating That NL-CVX1, A Computationally Designed De Novo Protein, Can Block Infection By SARS-CoV-2 Viral Variants of Concern
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced new data